dbSCI: A manually curated database of SARS-CoV-2 inhibitors forCOVID-19 br

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen of the ongoing coronavirusdisease 2019 (COVID-19) global pandemic. Here, by centralizing published cell-based experiments, clinical trials, andvirtual drug screening data from the NCBI PubMed database, we developed a database of SARS-CoV-2 inhibitors forCOVID-19, dbSCI, which includes 234 SARS-CoV-2 inhibitors collected from publications based on cell-basedexperiments, 81 drugs of COVID-19 in clinical trials and 1305 potential SARS-CoV-2 inhibitors from bioinformaticsanalyses. dbSCI provides four major functions: (1) search the drug target or its inhibitor for SARS-CoV-2, (2) browsetarget/inhibitor information collected from cell experiments, clinical trials, and virtual drug screenings, (3) download,and (4) submit data. Each entry in dbSCI contains 18 types of information, including inhibitor/drug name, targetingprotein, mechanism of inhibition, experimental technique, experimental sample type, and reference information. Insummary, dbSCI provides a relatively comprehensive, credible repository for inhibitors/drugs against SARS-CoV-2and their potential targeting mechanisms and it will be valuable for further studies to control COVID-19

[Clinical update in critical care of pulmonary medicine 2022].

In this review, we outlined the clinical studies in critical care field of pulmonary medicine from October 1, 2021 to September 30, 2022. For critically ill patients, frailty before disease onset was a predictor of mortality with increasing ICU length of stay, and the complaints of dyspnea in intubated phase was independently associated with posttraumatic stress disorder. Compared with transbronchial lung biopsy (TBLB) for patients with acute hypoxemic respiratory failure, transbronchial lung cryobiopsy (TBLC) had a positive significance to in leading to an increased chance of establishing a more accurate diagnosis, which could significantly improve the patients' prognosis. M-ROSE (microbiological rapid on-site evaluation) had high diagnostic value for lower respiratory tract pathogens, and the application of M-ROSE in the ICU could contribute to promoting a decrease in patients' inflammation levels and reducing the mortality of patients with invasive mechanical ventilation. EIT (electrical impedance tomography), DPL (transpulmonary driving pressure) and DPaw (airway driving pressure) had excellent positive values on dynamic assessment, guiding individualized respiratory support and prognostic evaluation. In critically ill hospitalized patients with COVID-19 who had received invasive mechanical ventilation or extracorporeal membrane oxygenation, treatment with baricitinib compared with placebo (in combination with standard of care, including corticosteroids) might reduce mortality. Delayed antimicrobial treatment significantly increased the incidence of severe infection and the mortality of shock patients, however, timing of antimicrobial therapy and control of the source of infection was critical. NIV (non-invasive ventilation) alternating with high-flow nasal oxygen immediately after extubation significantly decreased the risk of reintubation and death compared with high-flow nasal oxygen alone in obese or overweight patients at high risk of extubation failure. The effect of Pes-guided positive end-expiratory pressure (PEEP), compared with empirical high PEEP, was associated with lower mortality for more severe acute respiratory distress syndrome (ARDS) ventilated patients (APACHE Ⅱ>27.5). Prone-positioning during veno-venous extracorporeal membrane oxygenation was safe and effective and was associated with a higher probability of surviving and being weaned-off extracorporeal membrane oxygenation at 90 days. Therefore, individualized respiratory support strategies based on dynamic monitoring and assessment were essential for critically ill patients.

[Strengthening basic and clinical research on ocular infection caused by coronavirus].

This article was published ahead of print on the official website of Chinese Jounal of Ophthalmology on February 19, 2020. The prevention and treatment of coronavirus disease 2019 (COVID-2019) has reached the critical stage in China. Ocular surface represents a possible route for infection. Based on the previous studies and our own research, we summarize the potential transmission route and clinical symptoms of COVID-2019 in the eye, as well as the further prevention and research, with the expectation of contributing to the development in the field of infectious eye disease in China. (Chin J Ophthalmol, 2020, 56:250-252).

[Respiratory support for severe 2019-nCoV pneumonia suffering from acute respiratory failure: time and strategy].

Respiratory support is a very important technique for saving severe 2019-nCoV pneumonia patients who suffering respiratory failure, which can improve oxygenation, reduce mortality. Therefore, how to reasonable using respiratory support technique is the key point that relating success or failure. In this paper, the authors introduce their experience on treating severe 2019-nCoV pneumonia, it is hopeful for current fighting against 2019-nCoV in China.